Tegaserod inhibits the serotonin transporter SERT

Digestion

Volumn 75, Issue 2-3, 2007, Pages 90-95

  Ismair, Manfred G ^a   Kullak Ublick, Gerd A ^a   Blakely, Randy D ^b   Fried, Michael ^a   Vavricka, Stephan R ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Irritable bowel syndrome; Motility; Prokinetics; Visceral sensitivity

Indexed keywords

DOPAMINE TRANSPORTER; NORADRENALIN TRANSPORTER; SEROTONIN; SEROTONIN 4 RECEPTOR; SEROTONIN TRANSPORTER; TEGASEROD; TRITIUM;

ARTICLE; CELL STRAIN HEK293; CONTROLLED STUDY; EMBRYO; HUMAN; HUMAN CELL; INTESTINE WALL; KINETICS; PRIORITY JOURNAL;

CELLS, CULTURED; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; HUMANS; INDOLES; KIDNEY; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; RECEPTORS, SEROTONIN, 5-HT4; SEROTONIN; SEROTONIN AGONISTS; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SIGNAL TRANSDUCTION;

EID: 34548313976     PISSN: 00122823     EISSN: None     Source Type: Journal    
DOI: 10.1159/000102962     Document Type: Article

References (32)

1. Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine EJ, Muller-Lissner SA: Functional bowel disorders and functional abdominal pain. Gut 1999;45(suppl 2):II43-II47.
2. Gershon MD: Nerves, reflexes, and the enteric nervous system: pathogenesis of the irritable bowel syndrome. J Clin Gastroenterol 2005;39:S184-S193.
3. Erspamer V, Testini A: Observations on the release and turnover rate of 5-hydroxytryptamine in the gastrointestinal tract. J Pharm Pharmacol 1959;11:618-623.
4. Chen NH, Reith ME, Quick MW: Synaptic uptake and beyond: the sodium- and chloride-dependent neurotransmitter transporter family SLC6. Pflügers Arch 2004;447:519-531.
5. Chen JJ, Li Z, Pan H, Murphy DL, Tamir H, Koepsell H, Gershon MD: Maintenance of serotonin in the intestinal mucosa and ganglia of mice that lack the high-affinity serotonin transporter: abnormal intestinal motility and the expression of cation transporters. J Neurosci 2001;21:6348-6361.
6. Fuller RW, Wong DT: Serotonin uptake and serotonin uptake inhibition. Ann NY Acad Sci 1990;600:68-78.
7. Gorard DA, Libby GW, Farthing MJ: 5-Hydroxytryptamine and human small intestinal motility: effect of inhibiting 5-hydroxytryptamine reuptake. Gut 1994;35:496-500.
8. Gorard DA, Libby GW, Farthing MJ: Treating functional gastrointestinal disorders with antidepressants. Am J Med 2000;108:756.
9. Prather CM, Camilleri M, Zinsmeister AR, McKinzie S, Thomforde G: Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome. Gastroenterology 2000;118:463-468.
10. Camilleri M: Review article: tegaserod. Aliment Pharmacol Ther 2001;15:277-289.
11. McLaughlin J, Houghton LA: The rationale, efficacy and safety evidence for tegaserod in the treatment of irritable bowel syndrome. Expert Opin Drug Saf 2006;5:313-327.
12. Fried M, Beglinger C, Bobalj NG, Minor R, Coello N, Michetti P; TegaSwiss Study Group: Tegaserod is safe, well tolerated and effective in the treatment of patients with non-diarrhoea irritable bowel syndrome. Eur J Gastroenterol Hepatol 2005;17:421-427.
13. Tack J, Muller-Lissner S, Bytzer P, Corinaldesi R, Chang L, Viegas A, Schnekenbuehl S, Dunger-Baldauf C, Rueegg P: A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation. Gut 2005;54:1707-1713.
14. Kamm MA, Müller-Lissner S, Talley NJ, Tack J, Boeckxstaens G, Minushkin ON, Kalinin A, Dzieniszewski J, Haeck P, Fordham F, Hugot-Cournez S, Nault B: Tegaserod for the treatment of chronic constipation: a randomized, double-blind, placebo-controlled multinational study. Am J Gastroenterol 2005;100:362-372.
15. 4 receptors. Ann NY Acad Sci 1998;861:267-268.
16. 4 receptor partial agonist with promotile activity. Clin Pharmacokinet 2002;41:1021-1042.
17. Tonini M: 5-Hydroxytryptamine effects in the gut: the 3, 4, and 7 receptors. Neurogastroenterol Motil 2005;17:637-642.
18. 4 receptor partial agonist, accelerates gastric emptying and gastrointestinal transit in healthy male subjects. Aliment Pharmacol Ther 2001;15:1745-1751.
19. Talley NJ: Serotoninergic neuroenteric modulators. Lancet 2001;358:2061-2068.
20. Schutze K, Brandstatter G, Dragosics B, Judmaier G, Hentschel E: Double-blind study of the effect of cisapride on constipation and abdominal discomfort as components of the irritable bowel syndrome. Aliment Pharmacol Ther 1997;11:387-394.
21. Van Outryve M, Milo R, Toussaint J, Van Eeghem P: 'Prokinetic' treatment of constipation-predominant irritable bowel syndrome: a placebo-controlled study of cisapride. J Clin Gastroenterol 1991;13:49-57.
22. Farup PG, Hovdenak N, Wetterhus S, Lange OJ, Hovde O, Trondstad R: The symptomatic effect of cisapride in patients with irritable bowel syndrome and constipation. Scand J Gastroenterol 1998;33:128-131.
23. Atkinson W, Lockhart S, Whorwell PJ, Keevil B, Houghton LA: Altered 5-hydroxytryptamine signaling in patients with constipation-and diarrhea-predominant irritable bowel syndrome. Gastroenterology 2006;130:34-43.
24. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol 1997;340:249-258.
25. Li ZS, Pham TD, Tamir H, Chen JJ, Gershon MD: Enteric dopaminergic neurons: definition, developmental lineage, and effects of extrinsic denervation. J Neurosci 2004;24:1330-1339.
26. Thomas EM, Templeton D: Noradrenergic innervation of the villi of rat jejunum. J Auton Nerv Syst 1981;3:25-29.
27. Scheuermann DW, Stach W: Fluorescence microscopic study of the architecture and structure of an adrenergic network in the plexus myentericus (Auerbach), plexus submucosus externus (Schabadasch) and plexus submucosus internus (Meissner) of the porcine small intestine. Acta Anat (Basel) 1984;119:49-59.
28. Costa M, Furness JB: Somatostatin is present in a subpopulation of noradrenergic nerve fibres supplying the intestine. Neuroscience 1984;13:911-919.
29. Ramamoorthy S, Bauman AL, Moore KR, Han H, Yang-Feng T, Chang AS, Ganapathy V, Blakely RD: Antidepressant- and cocaine-sensitive human serotonin transporter: molecular cloning, expression, and chromosomal localization. Proc Natl Acad Sci USA 1993;90:2542-2546.
30. Galli A, DeFelice LJ, Duke BJ, Moore KR, Blakely RD: Sodium-dependent norepinephrine-induced currents in norepinephrine-transporter-transfected HEK293 cells blocked by cocaine and antidepressants. J Exp Biol 1995;198:2197-2212.
31. Gorard DA, Libby GW, Farthing MJ: Influence of antidepressants on whole gut and orocaecal transit times in health and irritable bowel syndrome. Aliment Pharmacol Ther 1994;8:159-166.
32. Scott LJ, Perry CM: Tegaserod. Drugs 1999;58:491-498.